Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller shows promise for post-surgery relief

NCT ID NCT05509868

Symptom relief Sponsor: Pharmbio Korea Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new pain medication called PBK_L1704 in 182 people who had foot surgery (bunionectomy) in South Korea. The goal was to see if it relieves moderate to severe pain better than a placebo over 48 hours. Participants received either the drug or a placebo, and pain levels were measured using a standard 0-10 scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

182 people

The number who actually took part.

Started

Jul 2022

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scheduled to undergo primary, unilateral, first metatarsal bunionectomy with osteotomy and internal fixation * Able to understand and comply with the study procedures and requirements, and able to provide written informed consent before any study procedure. Exclusion Criteria: * Participated in another oliceridine clinical study. * Received any investigational drug, device or therapy within 35 days before surgery. * Clinically significant medical, surgical, postsurgical, psychiatric or substance abuse condition or history of such condition that could confound the interpretation of efficacy, safety or tolerability data in the study. * American Society of Anesthesiologists (ASA) Physical Status Classification System classification III or worse.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain

Contacts and locations

Locations

  • Seoul Asan medical Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.